Elk Grove Village, IL (PRWEB) February 16, 2010
Wake Pharma US, Inc. (Chicago, IL) is very pleased to announce the appointment of Dr. Milton Kondiles as an Assistant Medical Director & Podiatry Coordinator.
Dr. Milton Kondiles is a board certified foot and ankle surgeon and a fellow of the American College of Foot and Ankle Surgery. He has been in private practice for over 25 years and currently is the head podiatrist at Our Lady of Resurrection Hospital and the past chairman of podiatry at Lincoln West Hospital. He has been teaching foot and ankle surgery to residents for over 20 years. He is a board member of several prestigious medical organizations and societies such as Advanced Foot and Ankle.
Dr. Kondiles has been on the front line in treating wounds for over twenty years and has vast experience with them. He has developed new innovative techniques in treating peripheral neuropathy which is often associated with wound ulcers. He is the director for the Clinics of Wellness and Neuropathy which treats neuropathic conditions.
Maggie Jankowski, COO of Wake Pharma US, Inc. commented, "Dr. Kondiles has been an important contributor to Wake Pharma US Inc. His extensive clinical insight and years of experience has been a tremendous asset to our organization. We believe that Dr. Kondiles will help us expand the presence of Wound Be Gone®."
Dr. Kondiles replied: "I am delighted to accept the position of Assistant Medical Director & Podiatry Coordinator and to have the opportunity to be part of this innovative Free Oxygen Radical Binding Technology."
He also stated: "In my many years of experience as a physician, I have used numerous wound care products. I have finally found a wound care product line that makes my daily regiment easier. Wound-Be-Gone is extremely effective for a wide spectrum of wound conditions. My results with using Wound-Be-Gone® in my office have proven that this product is highly successful for venous stasis ulcers, diabetic ulcerations and in post op nail procedures and the outcomes have been nothing short of dramatic."
Wound-Be-Gone is a topical gel developed to help accelerate wound healing. The active ingredient in Wound-Be-Gone® binds and neutralizes oxygen free radicals. Oxygen radicals are toxic substances known to cause inflammation and slow wound healing. The unique, revolutionary and patented formulation of Wound-Be-Gone® can be used for the treatment of minor injuries as well as for the clinical management of both acute and chronic wounds.
In addition to the wound healing properties of Wound-Be-Gone there are several other benefits that have been observed clinically. An important secondary benefit of Wound-Be-Gone is healing with minimized scar formation. Scar formation is accelerated in tissues with high levels of inflammation. By binding and neutralizing oxygen free radicals, Wound-Be-Gone decreases inflammatory pathways that can lead to tissue scarring. Additional benefits that have been observed with the use of Wound-Be-Gone® in clinical trials include reduction in pain and redness, which are also commonly associated with inflammation. Besides all of these benefits, Wound-Be-Gone® promises to significantly reduce the overall costs for treating wounds, and make it the most effective and efficient choice to treat acute and chronic wounds. Visit http://www.woundbegone.com for more details.
About Wake Pharma US, Inc:
Wake Pharma US, Inc. is an innovative and international company with its own manufacturing facility located in the Czech Republic (European Union). Wake Pharma US, Inc specializes in developing, marketing and distribution of revolutionary and unique products to the health marketplace. For further information about Wake Pharma US, Inc please visit our website at http://www.wakepharmaus.com
# # #